Research and Applications

Utilization and effects of mobile electronic clinical decision support on pediatric asthma care quality in the emergency department and inpatient setting

Ellen Kerns,1,2 Russell McCulloh,1,2 Sarah Fouquet,3 Corrie McDaniel,4 Lynda Ken,4 Peony Liu,5 and Sunitha Kaiser6,7

1Department of Pediatrics, University of Nebraska Medical Center, Omaha, Nebraska, USA, 2Division of Pediatric Hospital Medicine, Children’s Hospital and Medical Center, Omaha, Nebraska, USA, 3Department of Biomedical and Health Informatics, University of Missouri-Kansas City, Kansas City, Missouri, USA, 4Department of Pediatrics, University of Washington, Seattle, Washington, DC, USA, 5Department of Pediatrics, Kaiser Permanente Zion Medical Center, San Diego, California, USA, 6Departments of Pediatrics, Epidemiology and Biostatistics, University of California, San Francisco, California, USA, and 7Philip R. Lee Institute for Health Policy Studies, San Francisco, California, USA

Corresponding Author: Ellen Kerns, MPH, Department of Pediatrics, 982185 Nebraska Medical Center, University of Nebraska Medical Center, Omaha, NE 68198-2165, USA (ellen.kerns@unmc.edu)

Received 4 October 2020; Revised 5 January 2021; Editorial Decision 19 February 2021; Accepted 3 March 2021

ABSTRACT

Objective: To determine utilization and impacts of a mobile electronic clinical decision support (mECDS) on pediatric asthma care quality in emergency department and inpatient settings.

Methods: We conducted an observational study of a mECDS tool that was deployed as part of a multidimensional, national quality improvement (QI) project focused on pediatric asthma. We quantified mECDS utilization using cumulative screen views over the study period in the city in which each participating site was located. We determined associations between mECDS utilization and pediatric asthma quality metrics using mixed-effect logistic regression models (adjusted for time, site characteristics, site-level QI project engagement, and patient characteristics).

Results: The tool was offered to clinicians at 75 sites and used on 286 devices; cumulative screen views were 4191. Children’s hospitals and sites with greater QI project engagement had higher cumulative mECDS utilization. Cumulative mECDS utilization was associated with significantly reduced odds of hospital admission (OR: 0.95, 95% CI: 0.92–0.98) and higher odds of caregiver referral to smoking cessation resources (OR: 1.08, 95% CI: 1.01–1.16).

Discussion: We linked mECDS utilization to clinical outcomes using a national sample and controlling for important confounders (secular trends, patient case mix, and concomitant QI efforts). We found mECDS utilization was associated with improvements in multiple measures of pediatric asthma care quality.

Conclusion: mECDS has the potential to overcome barriers to dissemination and improve care on a broad scale. Important areas of future work include improving mECDS uptake/utilization, linking clinicians’ mECDS usage to clinical practice, and studying mECDS’s impacts on other common pediatric conditions.

Key words: clinical decision support, mobile applications, clinical practice guideline, guideline adherence, quality improvement

© The Author(s) 2021. Published by Oxford University Press on behalf of the American Medical Informatics Association. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
LAY SUMMARY
Childhood asthma is a leading cause of emergency visits, hospitalizations, missed school days, and missed work days for caregivers. Our team developed and launched a mobile decision support tool (app) as part of a national quality improvement (QI) project focused on pediatric asthma care. The application provided evidence-based decision support for management of asthma exacerbations for children in the emergency department and inpatient setting. Children’s hospitals and sites with greater overall QI project engagement were more likely to use the application. Cumulative application use was associated with improvements in pediatric asthma care, including reduced odds of hospital admission (OR: 0.95, 95% CI: 0.92–0.98) and higher odds of caregiver referral to resources for quitting smoking (OR: 1.08, 95% CI: 1.01–1.16). To our knowledge, our study is the first to link app use to clinical outcomes using a national sample and controlling for important potential confounders (time trends, patient characteristics, QI project engagement). Decision support in app form has the potential to overcome barriers to dissemination and improve care quality on a broad scale. Important areas of future work include improving app utilization, linking clinicians’ app usage to clinical practice, and studying app’s impacts on other common pediatric conditions.

BACKGROUND AND SIGNIFICANCE
New medical evidence takes an average of 17 years to enter into widespread clinical practice. Although healthcare institutions try to expedite the dissemination and implementation of evidence-based practices through the production of clinical decision support (CDS) tools, CDS development is resource-intensive, with limited portability across institutions. Even simpler decision support available in most electronic health record (EHR) systems, such as order sets, faces many barriers to and delays to implementation. Mobile electronic clinical decision support (mECDS) tools, when deployed through a freely downloadable app, have the potential to be an effective and scalable resource for improving quality of care and health outcomes. These tools also have been shown to integrate well into clinical workflow and reduce provider cognitive demand, improve medication dosing accuracy, aid with symptom recognition, and increase diagnostic and triage accuracy.

While mECDS tools have the potential to broadly and efficiently improve care quality, studies to date have left important knowledge gaps. Most studies to date assessing the impacts of mECDS on clinical practice have been conducted in simulated settings. A few studies that have assessed mECDS impacts on real-world practice consisted of simple pre-post analyses, which are subject to confounding biases from overall trends in healthcare delivery and changes in patient severity/case-mix over time. Prior randomized-controlled trials of mECDS have not quantified the cumulative effects of mECDS utilization on clinician practice or explored the effects of mECDS at the hospital/facility level. In a recent observational study, members of our team leveraged aggregate mECDS utilization data to determine the effects of mECDS on site-level care quality for infants with fever in the American Academy of Pediatrics (AAP) Value in Inpatient Pediatrics (VIP) network quality improvement (QI) project, REVISE. However, this study did not account for overall site project engagement (eg, other QI activities that could impact care quality), and the study only examined impact on practice in the emergency department (ED) setting.

Childhood asthma is a leading cause of emergency visits, hospitalizations, missed school days, and missed work days for caregivers, with total estimated direct costs of approximately $6 billion annually in USA. In 2018, VIP launched a new national QI project entitled PIPA, Pathways for Improving Pediatric Asthma Care. The project supported clinical pathway implementation with the global aim of “improving the value of care delivered to children with asthma.” PIPA included a diverse sample of EDs and inpatient wards across the country.

OBJECTIVE
Our team developed and launched a mECDS tool as part of PIPA, a multi-dimensional QI project. The mECDS tool provided evidence-based decision support for both inpatient and ED management of asthma exacerbations in children. The PIPA project collected data on site-level project engagement (other QI/implementation activities) and pediatric asthma care quality monthly. Our team used these data to achieve our objective—to determine the impact of mECDS use on pediatric asthma care quality in the ED and inpatient setting.

MATERIALS AND METHODS
Study design and setting
We conducted a longitudinal, observational study using data from the PIPA project. Recruitment of PIPA sites occurred via 3 e-mails to VIP electronic mailing lists (listservs). These listservs include clinicians from over 250 EDs and hospitals in the USA that range widely in size, type (eg, free-standing children’s hospitals, community hospitals), ownership model (eg, private, non-profit), and location (eg, rural, urban). To adequately support the QI project, VIP had PIPA sites to initiate the QI project in 2 waves, with half starting improvement activities in January 2018 and half starting in April 2018 (completing in December 2018 and March 2019, respectively). Our mECDS tool was released to PIPA sites in late August 2018. Core elements of this multi-dimensional QI project were designed using existing QI and implementation frameworks (the Institute for Healthcare Improvement’s Model for Improvement and the Consolidated Framework for Implementation Research). Participating EDs and hospitals were provided a pediatric asthma pathway implementation toolkit, which included sample evidence-based pathways and sample order sets based on pathway content. Each site designated a local physician implementation leader. These leaders recruited and then worked with local multidisciplinary teams to tailor and implement the pathways to fit local needs and context. Sites were provided several additional resources for implementation support: external practice facilitators, QI training, monthly audit and feedback, and educational seminars (eg, evidence-based asthma care).
Development and function of the mECDS tool
The PIPA mECDS tool (Figure 1A) was developed using the human factors methods including heuristic analysis and iterative usability testing.14 The tool consisted of ED and inpatient pediatric asthma pathways (Figure 1E) that calculated a patient’s severity score based on clinical parameters (eg, respiratory rate, wheezing, breath sounds, etc.) specified by the user at the time of assessment (Figure 1B). The pathways then provided evidence-based management recommendations based on the calculated severity score. The ED pathway provided criteria for ordering chest radiography and reminders to promptly administer steroids as indicated (Figure 1C). The inpatient pathway included guidance on MDI dosing and administration as well as reminders and tools for screening for secondhand tobacco exposure (Figure 1D). The mECDS tool also provided a selection of other tools that reinforced clinician adherence to the selected quality measures (Figure 1F) including links to smoking cessation resources (Figure 1F) and MDI administration tutorials (Figure 1G).

Deployment of the mECDS tool within PIPA
The tool was released in August 2018 as an available update to the pre-existing PedsGuide app. The PedsGuide app was released in 2015 for use in a prior VIP project. The app is free to download from both the iOS and Android app stores and requires no registration to begin using. The free mECDS tool release was announced to PIPA sites both via videoconference and email during project launch. However, there was then a 6 month delay before the tool was released leaving uptake of the tool to be largely driven by passive deployment methods including word of mouth and users having already downloaded the app for the prior VIP project.

PIPA site-reported data collection
Participating site characteristics such as hospital size and location (rural vs urban) were collected at project initiation via electronic survey. Site project engagement (QI activities) was assessed monthly via electronic survey of each site’s physician implementation leader. Surveys collected data on QI/implementation activities, specifically the state of implementation of key clinical pathway elements (eg, criteria for ordering chest radiography).15 Responses were converted into binary indicator variables that indicated whether each pathway element was implemented and in-use during the respective intervention month. Clinical practice data, including patient characteristics, adherence to performance metrics, and balancing metrics, were

Figure 1. PIPA mECDS pathways and other tools. (A) mECDS within the overall app PedsGuide; (B) severity score calculator; (C) example ED pathway end screen; (D) example inpatient pathway end screen; (E) pathway selection screen; (F) other resource selection screen; (G) smoking cessation resource; (H) MDI administration tutorial.
collected via chart review. A trained clinician from each site entered the chart review data on each ED visit/hospital admission into a secure, web-based electronic database (REDCap) maintained by the University of California, San Francisco. Sites collected chart review data on ED visits/admissions that occurred from January 2017 to March 2019. Most fields used in this analysis were required for chart submission by sites. Less than 2% of charts had missing data for the few non-required fields, and these were excluded from the analysis.

**mECDS tool utilization data collection**

mECDS tool utilization data were collected from release (August 23, 2018) to the end of the study period (March 31, 2019) using Google Analytics. Google Analytics automatically records mECDS utilization in terms of distinct devices on which the overall app has been opened (users), number of times the tool has been used (sessions), and what pages were viewed/buttons were clicked within the tool (events). Time stamps of the hour and geolocation of each session by city are also recorded. City-level usage data was linked by study site location for comparisons across sites. There were no cities with more than one site. For this analysis, we analyzed users, sessions, and events related to the newly-developed asthma mECDS tool within PedsGuide. Events were dichotomized according to whether they led the user to view quality metric-related content (MetricHits).

**Primary predictor**

In the prior REVISE study, we found cumulative mECDS utilization was associated with care quality for infants with fever. Cumulative utilization may reflect accumulated knowledge gained by use of the tool over time; thus, this cumulative utilization was used as the primary predictor in this study (cumulative metric hits). We determined “cumulative metric hits” by summing metric-related screen views by all asthma mECDS tool users in each city to date, from the city’s first month of usage data through the month immediately preceding the index month. For example, the value for October was computed by summing the city’s metric hits from mECDS release through September. The measure was set to zero for the first release month (August 2018).

**Outcomes**

Study performance and balancing metrics were selected through a consensus process among the national expert panel assembled for this study by the AAP. Performance metrics in the ED setting included decreasing the utilization of chest radiography (chest X-ray); increasing the use of severity assessment at ED triage (triage assessment); and decreasing the time from ED arrival to systemic corticosteroids administration (time to steroids). The balancing metric for the ED was not increasing ED length of stay. In the inpatient setting, the performance metrics were decreasing length of hospital stay; increasing early administration of metered dose inhalers (MDI, early defined as MDI at admission or first ordered at 1–2 h frequency); increasing documented screening for secondhand tobacco smoke exposure (Smoke Screening); and, when positive, increasing referral of caregivers to smoking cessation resources (Smoke Referral). The balancing metric was not increasing hospital readmission within 7 days of discharge (7-day readmit).

**Statistical analyses**

We analyzed the relationship between patient characteristics and cumulative metric hits in the city-month in which they were seen using an ANOVA test for patient age and chi-squared tests for all others. The relationship between site characteristics and cumulative metric hits in each site’s city in the final intervention month was analyzed using Fischer’s exact tests. Crude case adherence to each metric was tested using chi-squared tests for binary metrics and Mann-Whitney U-tests for continuous metrics.

To determine associations between cumulative metric hits and quality metrics, we used generalized mixed effect logistic regression models (1 per outcome/quality metric). The cutoff to derive odds ratios of case adherence by city-month cumulative metric hits was determined empirically by using the upper quartile of city-site use (5+ cumulative metric hits). A binomial distribution was used for binary metrics and a Gaussian distribution was used for continuous metrics. A log-link was used to compute ORs for continuous metrics (eg, odds of longer/prolonged LOS between kids seen in cities and months with 5+ cumulative metric hits vs <5 cumulative metric hits). Given clustering of encounters within sites, a random site intercept was included in each model. To account for potential confounders including secular trends/time, patient case-mix, and overall QI engagement, we included the following explanatory variables: cumulative metric hits, study month, site characteristic variables (eg, location, teaching status), site project engagement variables (eg, implementation of QI interventions), and patient characteristics (insurance type, sex, age, and prior use of inhaled corticosteroids). Metric Models: CaseAdherence = CumulativeMetricHits + Month + SiteCharacteristics + SiteProjectEngagement + PatientCharacteristics + RandomSiteIntercept.

All analyses were conducted using R v. 3.4.1 (Vienna, Austria), and p-values < .05 were considered significant.

**RESULTS**

**Overall mECDS utilization**

A total of 89 sites were recruited for the PIPA study and 75 sites completed the study. Reasons for not completing included lack of support from hospital leadership/administrators, difficulty obtaining local institutional review board (IRB) approval, difficulty obtaining chart review data, staff turnover, difficulty due to competing QI projects and very low patient volumes. In total, the tool was used on 286 devices, 335 times, incurring 4191 events, of which 922 (22%) were page views of quality metric-related content (MetricHits). Usage trends from release until the end of the intervention are depicted in Figure 2. Users of the tool consistently engaged with it about once per month on average and had about 1 metric hit per session. Overall, the inpatient pathway and ED pathway were used roughly the same number of times (205 vs 190). The metric-related content most often viewed, particularly in early months, was secondhand tobacco smoke screening tools, followed by chest x-ray criteria. Guidance on ED management/timely steroid administration were second most viewed overall and surpassed smoke screening in some of the later months. Guidance on metered-dose inhaler dosing was consistently viewed least often. Site locations and city-level cumulative metric hits are depicted in Figure 3.

**Patient-level predictors of mECDS utilization and quality metric adherence**

Patient characteristics, care setting, and crude adherence to metric are depicted in Table 1 by the level of cumulative use in the city and month in which their encounter occurred. Higher levels of cumula-
Figure 2. Monthly tool utilization during the PIPA project. (A) Unique users (number of devices on which the tool was used), sessions (number of times the tool was used), and MetricHits (views of metric-related content) in each month; (B) number of sessions involving the ED pathway, inpatient pathway, and other tools in each month; (C) number of times content related to each ED metric was viewed in each month; (D) number of times content related to each inpatient metric was viewed in each month.

Figure 3. Map of PIPA sites by cumulative metric hits in the intervention period.
tive metric hits were associated with patient-level prior prescription of an inhaled corticosteroid, having a payor type of “other,” and being seen in the inpatient setting.

Site-level predictors of mECDS utilization

Most cities with a study site (61%) had at least some use, but cities with free-standing children’s hospitals had higher levels of use than those with community hospitals or non-freestanding children’s hospitals (Table 2). Sites with higher QI project engagement had significantly higher mECDS utilization, specifically those that implemented the pathway elements MDI dosing guidance, bronchodilator protocol, and discharge criteria.

Associations between mECDS utilization and care quality

City-level cumulative metric hits were associated with one ED quality metric (Figure 4). Children seen in a city and month with 5 additional cumulative metric hits were 5% less likely to be admitted to the hospital (OR: 0.95, 95% CI: 0.92–0.98). City-level cumulative metric hits were associated with 2 inpatient quality metrics (Figure 5). Children seen in a city and month with 5 additional cumulative metric hits had a reduction in odds of prolonged hospital length of stay (OR: 0.99, 95% CI: 0.98–0.99) and were also more likely to have a caregiver referred to smoking cessation resources (OR: 1.08, 95% CI: 1.01–1.16).

DISCUSSION

To our knowledge, this is the first study of the cumulative effects of a mECDS tool on care quality that uses a large, national sample and robust methods to address potential confounding biases (secular trends, case-mix differences, concomitant QI efforts). We found that the mECDS tool was used in most cities with a project site and that cumulative mECDS utilization was associated with improvements in the quality of asthma care for children, including reduced odds of hospital admission, reduced inpatient length of stay, and higher odds of referral of caretakers to smoking cessation resources. These findings align with those of our prior study of a mECDS tool for management of infants with fever, in which the tool was also associated with improvements in 3 quality metrics.7 Our findings also reinforce existing evidence from randomized controlled trials that mECDS tools can have positive impacts on clinicians’ guideline ad-

### Table 1. Patient characteristics and metric adherence by cumulative use in the city and month of encounter.

|                      | Total           | 0              | 1–4             | 5+              | P-value |
|----------------------|-----------------|----------------|-----------------|-----------------|---------|
| Total patients       | 34 121          | 29 484 86%     | 2216 6%         | 2421 7%         | <.001   |
| Age (years)          | Mean (SD)       | 7 4            | 7 4             | 7 4             | .585    |
| Male                 | 20 577 60%      | 17 804 60%     | 1337 60%        | 1436 59%        | <.001   |
| Female               | 13 544 40%      | 11 680 40%     | 879 40%         | 985 41%         | <.001   |
| Insurance type       | n (%)           |                |                 |                 |         |
| Public               | 13 039 38%      | 11 242 38%     | 897 40%         | 909 37%         | <.001   |
| Private              | 5512 16%        | 4716 16%       | 432 19%         | 364 15%         | .024    |
| Tricare              | 191 1%          | 168 1%         | 14 1%           | 9 0%            | .024    |
| Other                | 1857 5%         | 1583 5%        | 85 4%           | 189 8%          | .024    |
| Prior prescription of inhaled corticosteroid | n (%) |                |                 |                 |         |
| Yes                  | 15 724 46%      | 13 409 45%     | 1042 47%        | 1273 53%        | <.001   |
| No                   | 18 397 54%      | 16 075 55%     | 1174 53%        | 1148 47%        | <.001   |
| Setting              | n (%)           |                |                 |                 |         |
| ED                   | 22 109 65%      | 19 198 65%     | 1440 65%        | 1471 61%        | <.001   |
| Chest X-ray          | n (%)           |                |                 |                 | <.001   |
| Triage assessment    | 19 866 90%      | 17 183 90%     | 1395 97%        | 1288 88%        | <.001   |
| Time to steroids (min) | Median (IQR)   | 49 (30–81)     | 49 (30–82)      | 50 (32–81)      | 43 (28–69) | <.001 |
| Admission            | n (%)           |                |                 |                 | <.001   |
| ED LOS (min)         | Median (IQR)    | 4219 (102–208) | 3598 (102–209)  | 359 (102–209)   | 262 (102–209) | <.001 |
| Inpatient            | n (%)           |                |                 |                 | <.001   |
| Inpatient LOS (h)    | Median (IQR)    | 12 012 35%     | 10 286 35%      | 776 35%         | 950 39% | <.001 |
| MDI                  | n (%)           |                |                 |                 | <.001   |
| Smoke screening      | n (%)           |                |                 |                 | <.001   |
| Smoke referral       | n (%)           |                |                 |                 | <.001   |
| 7-day readmit        | n (%)           |                |                 |                 | <.001   |

*a*ANOVA test.  
*b*Chi-squared test.  
*c*Mann–Whitney U-test.  

6 JAMIA Open, 2021, Vol. 4, No. 2
We found that cumulative utilization of the mECDS tool was associated with improvements in 3 quality measures: hospital admission from the ED, inpatient length of stay, and referral of caretakers to smoking cessation resources. Guidelines recommend timely administration of bronchodilators and systemic corticosteroids for children with asthma exacerbations because timely administration decreases time to recovery and risk of hospital admission. Although we did not detect statistically significant changes in timely systemic corticosteroid administration, the mECDS tool may have supported other aspects of more timely care, such as severity assessment or administration of bronchodilators, thus driving our finding of lower hospital admission risk. It is also possible that use of the tool increased clinician recognition of moderate to severe patients speeding up the triage process and decreasing admission risk. Bronchodilator weaning protocols/pathways and standardized discharge criteria can also decrease hospital length of stay. Clinician use of these resources within the tool may have contributed to our findings of decreased length of inpatient stay. Lastly, we included a sec-

### Table 2. Hospital/ED characteristics by cumulative metric hits in the final intervention month.

| Total sites | Cumulative metric hits |
|-------------|------------------------|
|             | 0         | 1–4      | 5+      |
| n           | %         | n        | %       | n        | %    |
| Site-level factors |           |           |           |           |
| Hospital location |           |           |           |           |
| Urban        | 33        | 10       | 14       | 22       |
| Suburban     | 37        | 17       | 14       | 27       |
| Rural        | 5         | 2        | 1        | 2%       |
| Hospital type |           |           |           |           |
| Community    | 40        | 21       | 12       | 32       |
| Non-freestanding children’s | 23        | 6        | 9        | 36       |
| Free-standing children’s | 12        | 2        | 3        | 32       |
| Hospital teaching status |           |           |           |           |
| Yes          | 68        | 27       | 23       | 82       |
| No           | 7         | 9        | 4        | 18       |
| Hospital bed size |           |           |           |           |
| Large (>250 beds) | 46        | 19       | 13       | 64       |
| Medium (100–249 beds) | 21        | 7        | 8        | 27       |
| Small (<100 beds) | 7         | 2        | 3        | 9%       |
| QI project engagement (pathway elements implemented): ED |           |           |           |           |
| CXR criteria | 36        | 48       | 13       | 45       |
| Severity scoring tool | 51        | 68       | 16       | 55       |
| Order set for corticosteroids | 27        | 36       | 8        | 28       |
| QI project engagement (pathway elements implemented): inpatient |           |           |           |           |
| MDI dosing guidance | 60        | 80       | 17       | 59       |
| Bronchodilator protocol | 51        | 68       | 14       | 48       |
| Discharge criteria | 57        | 76       | 16       | 55       |
| Tobacco screening reminder | 63        | 84       | 20       | 69       |
| Cessation tool referral reminder | 62        | 83       | 20       | 69       |

*aFisher’s exact test.*

![Figure 4](https://academic.oup.com/jamiaopen/article/4/2/ooab019/6236340)

Figure 4. Effects of 5 additional cumulative metric hits on ED quality metrics. Odds of case adherence to each ED metric in a given month and city with 5+ cumulative metric hits versus <5 cumulative metric hits (adjusted for site characteristics, site engagement, patient case mix, study month, and clustering by site).

![Figure 5](https://academic.oup.com/jamiaopen/article/4/2/ooab019/6236340)

Figure 5. Effects of 5 additional cumulative metric hits on inpatient quality metrics. Odds of case adherence to each inpatient metric in a given month and city with 5+ cumulative metric hits versus <5 cumulative metric hits (adjusted for site characteristics, site engagement, patient case mix, study month, and clustering by site).
tion within the mECDS tool that could be shared in real time with caretakers to provide smoking cessation resources, and this resource was highly utilized compared to others within the tool. This resource may have helped drive our findings of increased smoking cessation resource referral.

The overall effects of the mECDS tool were small compared to prior studies of QI interventions, including the REVISE study that examined associations between cumulative mECDS utilization and care quality for febrile infants. Recent pediatric asthma studies have shown larger magnitude improvements in rates of hospital admission from the ED (OR 0.53 [95% CI: 0.37–0.76] shown by Bekmezian et al.,22 OR 0.63 [95% CI: 0.40–0.99] shown by Walls et. al23) length of inpatient stay (decreases of approximately 8–9%24,25) and guideline adherence measures, such as referral of caretakers to smoking cessation resources.26 These findings underscore the importance of our analysis accounting for site project engagement/other QI and implementation activities. However, such QI activities, particularly those that involve implementation within the EHR, are labor intensive and not as easily disseminated across institutions as mECDS tools. Thus, mECDS tool may still play an important role in QI when adequate resources for QI interventions are not available, as well as a supplemental tool for increasing the effects of QI interventions.

Although utilization was similar overall for the ED and inpatient pathways, the volume of patients seen in the ED was much higher (~22,000 in ED vs ~12,000 in the inpatient setting), perhaps indicating that the inpatient pathway had more uptake. This finding aligns with the greater impact of the tool on inpatient metrics. Free standing children’s hospitals are often repeat participants of VIP’s QI projects; thus, clinicians at these sites may have already had had the app the tool was deployed within. Sites also had higher overall project engagement/implementation of key pathway elements in the inpatient versus ED setting (68–84% vs 36–68%). Previous studies have shown that such project engagement is often unmeasured or only available via project leader self-report.27 The association found between self-reported project engagement/implementation and mECDS utilization indicates that mECDS utilization may be a good proxy for project engagement. This finding also supports the validity of self-reported project engagement.

This study had several limitations. First, despite harnessing using human factors methods (heuristic analysis, iterative usability testing) to develop the mECDS tool and widely disseminating it, mECDS tool uptake and usage was low. This may have been due to delays in launching the tool (about 6 months after the launch of the QI intervention), concomitant delivery of multiple QI interventions, or lack of explicit application of behavior change theory to mECDS use (though theory/frameworks were used in design of the overall QI intervention).3,13 Our team did also conduct a mixed-methods study to better understand barriers to utilization of the QI interventions offered, including the mECDS tool.15 We found a potential barrier was lack of awareness, as many QI interventions were introduced within a relatively short time frame. When asked why they did not use the mECDS tool, participants reported they did not know it was available. The delayed launch also meant we were only able to track data for 6 months after launching the mECDS, so we did not evaluate sustainability of mECDS utilization. However, the eventual roll-out of the mECDS tool reached a large, diverse sample of both EDs and inpatient wards from all regions of the country and strengthens the generalizability of our results.

Second, the delay led to mECDS tool use to only in the Fall and early Winter. Seasonal differences in availability could have contributed to differences seen, as asthma cases overall are higher in the Fall and the Winter. Also, since many of the sites were teaching hospitals, this could lead to practice differences given the release’s correspondence with the beginning of the academic year with a new influx of staff and students. Unfortunately, we only had patient demographics that are correlates of patient severity and no direct measures of clinical severity, so we could not account for differing severity driven by season. However, models were adjusted for both time and teaching status, and we had comparison/control sites gathering outcome data at the same time/season (because of differing usage levels between sites).

Third, we were unable to directly tie usage to study sites or clinicians, but rather city of use. Thus, not all use in a city can be assumed to have come from the project site. However, this methodology has been previously used by us and others to study mECDS effects.7,28 Additionally, the tool was released freely and required no registration to use. While this method of deployment allowed for easier scalability across the diverse network of sites, it also prevented us from being able to analyze user characteristics or definitively tie their use to the project.

Finally, since our study links geographically based usage to aggregate practice level changes in care quality, the exact mechanism by which mECDS use led to these improvements cannot be determined. At the individual user level, the mECDS tool may have provided real-time tailored decision support on evidence-based practices and/or may have provided education that led to longlasting user behavior change at both the user and the site levels. While there may also be residual confounding bias from overall site QI engagement (which correlated with cumulative mECDS usage), we tried to account for this by including measures of project engagement in the adjusted models.

CONCLUSIONS

Mobile electronic clinical decision support has the potential to overcome barriers to dissemination and improve quality of care and health outcomes across institutions. To our knowledge, this report is the first of its kind to attempt to link clinical practice to mECDS utilization on a national scale that controls for important potential confounders including case-mix differences and concomitant local QI efforts. We found cumulative mECDS utilization was associated with improvements in multiple measures of pediatric asthma care quality. Important areas of future work include improving mECDS uptake/utilization, linking clinicians’ mECDS usage to behavior, and studying mECDS’s impacts on other common pediatric conditions.

ETHICAL CONSIDERATIONS

The PIPA study was approved by the AAP Institutional Review Board. Teams at each participating site obtained local institutional review board approvals, as necessary. This analysis was deemed non-human subject research by the University of Nebraska Medical Center Institutional Review Board.

FUNDING

This work was supported by the Office of the Director of the National Institutes of Health (grant number UG1OD024953) through support of Ms. Kerns and Dr. McCulloh’s time, and also by the Agency for Healthcare Research and Quality (grant number K08 HS024592) through support of Dr. Kaiser’s time.
CONFLICT OF INTEREST STATEMENT

None declared.

AUTHOR CONTRIBUTIONS

EK drafted the study design, helped to develop and test the mECDS tool, performed the analysis, and drafted the manuscript. RM participated in the study design, helped to develop and test the mECDS tool, reviewed the analysis, and revised the manuscript. SF participated in the study design, led the testing and development of the mECDS tool, reviewed the analysis, and revised the manuscript. CM participated in the study design, helped test the mECDS tool, reviewed the analysis, and revised the manuscript. PL helped test the mECDS tool and revise the manuscript. SK designed the PIPA quality improvement project, participated in study design and data analysis, and reviewed and revised the manuscript. All authors read and approved the final manuscript.

DATA AVAILABILITY STATEMENT

The data underlying this article cannot be shared publicly due to its potential to identify hospitals in association with their performance in the project described. The data will be shared on reasonable request.

REFERENCES

1. Morris ZS, Wooding S, Grant J. The answer is 17 years, what is the question: understanding time lags in translational research. J R Soc Med 2011; 104(12): 510–20.
2. Berner ES. Clinical decision support systems: state of the art. AHRQ publication 2009; 90069: 1–26.
3. Kaiser SV, Lam R, Cabana MD. Pediatric Research in Inpatient Settings (PRIS) Network, et al. Best practices in implementing inpatient pediatric asthma pathways: a qualitative study. J Asthma 2020; 57(7): 744–54.
4. Dwivedi R, Ghahramani F, Mahapatra R. Mobile Clinical Decision Support Systems – A Systematic Review. 2017.
5. Kubben P. Mobile apps. In: Kubben P, Dumontier M, Dekker A, eds. Fundamentals of Clinical Data Science. Cham: Springer International Publishing; 2019: 171–9.
6. Watson HA, Tribe RM, Shennan AH. The role of medical smartphone apps in clinical decision-support: a literature review. Artif Intell Med 2019; 100: 101707.
7. Kerns EK, Staggs VS, Fouquet SD, et al. Estimating the impact of deploying an electronic clinical decision support tool as part of a national practice improvement project. J Am Med Inform Assoc 2019; 26(7): 630–6.
8. Perry R, Brailleanu G, Palmer T, et al. The economic burden of pediatric asthma in the United States: literature review of current evidence. Pharmacoeconomics 2019; 37(2): 155–67.
9. Wier LM, Yu H, Owens PL, Washington R. Overview of children in the emergency department. 2010: Statistical Brief# 157.
10. Weiss A, Elixhauser A. Agency for Healthcare Research and Quality. Overview of Hospital Stays in the United States. 2014. Statistical brief# 180.
11. Kaiser SV, Jennings B, Rodean J, et al. Pathways for Improving Inpatient Pediatric Asthma Care (PIPA): a multicenter, national study. Pediatrics 2020; 145(6): e20193026.
12. Kaiser SV, Johnson MD, Walls TA, et al. Pathways to Improve Pediatric Asthma Care: a multisite, national study of emergency department asthma pathway implementation. J Pediatr 2020; 223: 100–107.
13. The Breakthrough Series: IHI’s Collaborative Model for Achieving Breakthrough Improvement | IHI - Institute for Healthcare Improvement. 2020. http://www.ihhi.org/80/resources/Pages/IHIWhitePapers/TheBreakthroughSeriesIHIItsCollaborativeModelforAchievingBreakthroughImprovement.aspx. Accessed December 29, 2020.
14. McCulloh RJ, Fouquet SD, Herigon J, et al. Development and implementation of a mobile device-based pediatric electronic decision support tool as part of a national practice standardization project. J Am Med Inform Assoc 2018; 25(9): 1175–82.
15. Gupta N, Cattamanchi A, Cabana MD, et al. Implementing pediatric inpatient asthma pathways. J Asthma 2020; 1–10. doi:10.1080/02770933.2020.1741612.
16. Health UD of Services H. National Heart, Lung and Blood Institute. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma (EPR-3 2007). NIH Item No. 08-4051. 2007.
17. Bhogal SK, McGillivray D, Bourbeau J, et al. Early administration of systemic corticosteroids reduces hospital admission rates for children with moderate and severe asthma exacerbation. Ann Emerg Med 2012; 60(1): 84–91.
18. Zemek R, Plint A, Osmond MH, et al. Triage nurse initiation of corticosteroids in pediatric asthma is associated with improved emergency department efficiency. Pediatrics 2012; 129(4): 671–80.
19. Pound CM, Gelt V, Akiki S, et al. Nurse-driven clinical pathway for inpatient asthma: a randomized controlled trial. Hosp Pediatr 2017; 7(4): 204–13.
20. Bartlett KW, Parente VM, Morales V, et al. Improving the efficiency of care for pediatric patients hospitalized with asthma. Hosp Pediatr 2017; 7(1): 31–8.
21. Chong C, Samson J, Di Lucia A, et al. Criteria led discharge reduces length of hospital stay for children with acute asthma. J Asthma 2016; 53(1): 1.
22. Bekmezian A, Fee C, Weber E. Clinical pathway improves asthma management in the emergency department and reduces admissions. J Asthma 2015; 52(8): 806–14.
23. Walls TA, Hughes NT, Mullan PC, et al. Improving pediatric asthma outcomes in a community emergency department. Pediatrics 2017; 139(1): e20160088.
24. Kaiser SV, Rodean J, Bekmezian A, Pediatric Research in Inpatient Settings (PRIS) Network, et al. Effectiveness of pediatric asthma pathways for hospitalized children: a multicenter, national analysis. J Pediatr 2018; 197: 165–71.
25. Nkoy F, Fassi B, Stone B, et al. Improving pediatric asthma care and outcomes across multiple hospitals. Pediatrics 2015; 136(6): e1602–e1610.
26. Rutman L, Atkins RC, Migita R, et al. Modification of an established pediatric asthma pathway improves evidence-based, efficient care. Pediatrics 2016; 138(6): e20161248.
27. Hempel S, O’Hanlon C, Lim YW, et al. Spread tools: a systematic review of components, uptake, and effectiveness of quality improvement toolkits. Implement Sci 2019; 14(1): 83.
28. Patel R, Green W, Shahzad MW, et al. Use of mobile clinical decision support software by junior doctors at a UK teaching hospital: identification and evaluation of barriers to engagement. JMIR mHealth uHealth 2015; 3(3): e80.